EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

New strategy to treat spinal cord injury: Nafamostat mesilate suppressed NLRP3-mediated pyroptosis during acute phase

Yongfu Lou, Zonghao Li, Han Zheng, Zhongze Yuan, Wenxiang Li, Jianping Zhang, Wenyuan Shen, Yiming Gao, Ning Ran, Xiaohong Kong, Shiqing Feng

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Yongfu Lou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Hospital, Cheeloo College of Medicine, Shandong University, Shandong, China; Shandong University Centre for Ort…. Hauptthemen laut MEDLINE: Benzamidines, Guanidines, NLR Family, Pyrin Domain-Containing 3 Protein, Pyroptosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal cord injury (SCI) is a devastating condition for which effective clinical treatment is currently lacking. During the acute phase of SCI, myriad pathological changes give rise to subsequent secondary injury. The results of our previous studies indicated that treating rats post-SCI with nafamostat mesilate (NM) protected the blood-spinal cord barrier (BSCB) and exerted an antiapoptotic effect. However, the optimal dosage for mice with SCI and the underlying mechanisms potentially contributing to recovery, especially during the acute phase of SCI, have not been determined. In this study, we first determined the optimal dosage of NM for mice post-SCI (5 mg/kg/day). Subsequently, our RNA-seq findings revealed that NM has the potential to inhibit pyroptosis after SCI. These findings were further substantiated by subsequent Western blot (WB) and Immunofluorescence (IF) analyses in vivo. These results indicate that NM can alleviate NLRP3 (NOD-like receptor thermal protein domain associated protein 3)-mediated pyroptosis by modulating the NF-κB signaling pathway and reducing the protein expression levels of NIMA-related kinase 7 (NEK7) and cathepsin B (CTSB). In vitro experimental results supported our in vivo findings, revealing the effectiveness of NM in suppressing pyroptosis induced by adenosine triphosphate (ATP) and lipopolysaccharide (LPS) in BV2 cells. These results underscore the potential of NM to regulate NLRP3-mediated pyroptosis following SCI. Notably, compared with other synthetic compounds, NM exhibits greater versatility, suggesting that it is a promising clinical treatment option for SCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidinesGuanidinesNLR Family, Pyrin Domain-Containing 3 ProteinPyroptosisSpinal Cord InjuriesAnimalsMaleMiceCathepsin BDisease Models, AnimalMice, Inbred C57BLNF-kappa BSignal Transduction

Stichwörter der Autor:innen

NLRP3Nafamostat mesilatePyroptosisSpinal cord injury

Substanzen

BenzamidinesCathepsin BGuanidinesnafamostatNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouse

Autor:innen und Institutionen

  • Department of Orthopedics, The Second Hospital, Cheeloo College of Medicine, Shandong University, Shandong, China; Shandong University Centre for Orthopaedics, Cheeloo College of Medicine, Shandong University, Shandong,…
  • Shandong University Centre for Orthopaedics, Cheeloo College of Medicine, Shandong University, Shandong, China; Department of Orthopaedics, Qilu Hospital of Shandong University, Shandong University, Shandong, China.
  • Division of Surgery and Interventional Science, University College London, London HA7 4LP, United Kingdom.
  • Shandong University Centre for Orthopaedics, Cheeloo College of Medicine, Shandong University, Shandong, China; Department of Orthopaedics, Qilu Hospital of Shandong University, Shandong University, Shandong, China. Ele…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lou, Y., Li, Z., Zheng, H., Yuan, Z., Li, W., Zhang, J., Shen, W., Gao, Y., Ran, N., Kong, X., & Feng, S. (2024). New strategy to treat spinal cord injury: Nafamostat mesilate suppressed NLRP3-mediated pyroptosis during acute phase. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112190

Vancouver

Lou Y, Li Z, Zheng H, Yuan Z, Li W, Zhang J, et al. New strategy to treat spinal cord injury: Nafamostat mesilate suppressed NLRP3-mediated pyroptosis during acute phase. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112190

BibTeX
@article{Lou2024,
  author = {Lou, Yongfu and Li, Zonghao and Zheng, Han and Yuan, Zhongze and Li, Wenxiang and Zhang, Jianping and Shen, Wenyuan and Gao, Yiming and Ran, Ning and Kong, Xiaohong and Feng, Shiqing},
  title = {New strategy to treat spinal cord injury: Nafamostat mesilate suppressed NLRP3-mediated pyroptosis during acute phase},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112190}
}
Kostenlos starten →